
    
      A multicenter Open-label, single-arm, phase I/II clinical trial is conducted on patients with
      histological stage IV gastric cancer given irinotecan plus S-1. The usefulness of this
      regimens as 1st line therapy for gastric cancer was evaluated by the disease-free survival
      rate (DFR), overall survival rate (OS), incidence and severity of adverse event.
    
  